These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37844348)

  • 21. Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration.
    Yoshida M
    Neuropathology; 2014 Dec; 34(6):555-70. PubMed ID: 25124031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.
    Nübling G; Schuberth M; Feldmer K; Giese A; Holdt LM; Teupser D; Lorenzl S
    Exp Brain Res; 2017 Aug; 235(8):2407-2412. PubMed ID: 28493068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The MAPT gene is differentially methylated in the progressive supranuclear palsy brain.
    Huin V; Deramecourt V; Caparros-Lefebvre D; Maurage CA; Duyckaerts C; Kovari E; Pasquier F; Buée-Scherrer V; Labreuche J; Behal H; Buée L; Dhaenens CM; Sablonnière B
    Mov Disord; 2016 Dec; 31(12):1883-1890. PubMed ID: 27709663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unexpected abundance of pathological tau in progressive supranuclear palsy white matter.
    Zhukareva V; Joyce S; Schuck T; Van Deerlin V; Hurtig H; Albin R; Gilman S; Chin S; Miller B; Trojanowski JQ; Lee VM
    Ann Neurol; 2006 Sep; 60(3):335-45. PubMed ID: 16823854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
    Williams DR; Holton JL; Strand C; Pittman A; de Silva R; Lees AJ; Revesz T
    Brain; 2007 Jun; 130(Pt 6):1566-76. PubMed ID: 17525140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations.
    Iovino M; Agathou S; González-Rueda A; Del Castillo Velasco-Herrera M; Borroni B; Alberici A; Lynch T; O'Dowd S; Geti I; Gaffney D; Vallier L; Paulsen O; Káradóttir RT; Spillantini MG
    Brain; 2015 Nov; 138(Pt 11):3345-59. PubMed ID: 26220942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series.
    Yoshida K; Hata Y; Kinoshita K; Takashima S; Tanaka K; Nishida N
    Acta Neuropathol; 2017 May; 133(5):809-823. PubMed ID: 28064358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration.
    Gentry EG; Henderson BW; Arrant AE; Gearing M; Feng Y; Riddle NC; Herskowitz JH
    J Neurosci; 2016 Jan; 36(4):1316-23. PubMed ID: 26818518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy.
    Roemer SF; Grinberg LT; Crary JF; Seeley WW; McKee AC; Kovacs GG; Beach TG; Duyckaerts C; Ferrer IA; Gelpi E; Lee EB; Revesz T; White CL; Yoshida M; Pereira FL; Whitney K; Ghayal NB; Dickson DW
    Acta Neuropathol; 2022 Oct; 144(4):603-614. PubMed ID: 35947184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy.
    Sakae N; Josephs KA; Litvan I; Murray ME; Duara R; Uitti RJ; Wszolek ZK; Graff-Radford NR; Dickson DW
    Mov Disord; 2019 Nov; 34(11):1655-1662. PubMed ID: 31433871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
    Ferrer I; Blanco R; Carmona M; Puig B
    J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A proteomic study identifies different levels of light chain ferritin in corticobasal degeneration and progressive supranuclear palsy.
    Ebrahim AS; Kulathingal J; Murray ME; Casey-Castanedes M; Dickson DW; Yen SH; Sevlever D
    Acta Neuropathol; 2011 Dec; 122(6):727-36. PubMed ID: 22012136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration.
    Martínez-Maldonado A; Ontiveros-Torres MÁ; Harrington CR; Montiel-Sosa JF; Prandiz RG; Bocanegra-López P; Sorsby-Vargas AM; Bravo-Muñoz M; Florán-Garduño B; Villanueva-Fierro I; Perry G; Garcés-Ramírez L; de la Cruz F; Martínez-Robles S; Pacheco-Herrero M; Luna-Muñoz J
    J Alzheimers Dis; 2021; 79(4):1517-1531. PubMed ID: 33459640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of modular gene co-expression networks reveals molecular pathways underlying Alzheimer's disease and progressive supranuclear palsy.
    Iohan LDCC; Lambert JC; Costa MR
    PLoS One; 2022; 17(4):e0266405. PubMed ID: 35421130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyramidal system involvement in progressive supranuclear palsy - a clinicopathological correlation.
    Stejskalova Z; Rohan Z; Rusina R; Tesar A; Kukal J; Kovacs GG; Bartos A; Matej R
    BMC Neurol; 2019 Mar; 19(1):42. PubMed ID: 30894142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Stage of Progressive Supranuclear Palsy: A Neuropathological Study of 324 Consecutive Autopsy Cases.
    Nogami A; Yamazaki M; Saito Y; Hatsuta H; Sakiyama Y; Takao M; Kimura K; Murayama S
    J Nippon Med Sch; 2015; 82(6):266-73. PubMed ID: 26823029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy.
    Katsuse O; Iseki E; Arai T; Akiyama H; Togo T; Uchikado H; Kato M; de Silva R; Lees A; Kosaka K
    Acta Neuropathol; 2003 Sep; 106(3):251-60. PubMed ID: 12802605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of phosphorylated tau protein interactors in progressive supranuclear palsy (PSP) reveals networks involved in protein degradation, stress response, cytoskeletal dynamics, metabolic processes, and neurotransmission.
    Radford RAW; Rayner SL; Szwaja P; Morsch M; Cheng F; Zhu T; Widagdo J; Anggono V; Pountney DL; Chung R; Lee A
    J Neurochem; 2023 May; 165(4):563-586. PubMed ID: 36847488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates.
    Darricau M; Katsinelos T; Raschella F; Milekovic T; Crochemore L; Li Q; Courtine G; McEwan WA; Dehay B; Bezard E; Planche V
    Brain; 2023 Jun; 146(6):2524-2534. PubMed ID: 36382344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.